STRIDE-7

In the Stride-7 study, we are investigating the safety and efficacy of a new pneumococcal vaccine in an HIV-positive population.

Pneumococci are mainly responsible for developing pneumonia. This vaccine should protect people better against other subtypes of the infection than current vaccines on the market. These subtypes are responsible for the majority of pneumonia cases. This phase 3 study is being run in collaboration with Merck Sharp & Dohme LLC (MSD), the study sponsor.

We started the study in September 2022 and plan to finish the study by the end of 2023. We included the maximum number of 15 participants in the study and are therefore no longer looking for additional participants.

Participants must have a confirmed HIV diagnosis and a minimum age of 18 years old. They may have already been vaccinated with other available pneumococcal vaccines on the market.

Some participants received a placebo, others the vaccine. Depending on this, the study lasts about 6 to 7 months, with 5 to 7 visits at the CTC. After each vaccination, our study doctors closely monitor any side effects.

For more scientific background on the study, please visit the publicly accessible official registration database.